[{"id":"198522b7-100a-4569-a5b1-c2c7d2835c3e","acronym":"","url":"https://clinicaltrials.gov/study/NCT06195306","created_at":"2024-01-08T16:17:49.869Z","updated_at":"2025-02-25T13:42:01.381Z","phase":"Phase 2","brief_title":"Low Dose Tamoxifen With or Without Omega-3 Fatty Acids for Breast Cancer Risk Reduction","source_id_and_acronym":"NCT06195306","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" FOXA1 • AGR2 • LEP","pipe":"","alterations":" ","tags":["FOXA1 • AGR2 • LEP"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e tamoxifen"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 66","initiation":"Initiation: 02/28/2025","start_date":" 02/28/2025","primary_txt":" Primary completion: 01/01/2027","primary_completion_date":" 01/01/2027","study_txt":" Completion: 01/01/2027","study_completion_date":" 01/01/2027","last_update_posted":"2025-02-21"},{"id":"251108c9-4fb9-4d2a-b2b3-ca1b2c0bb048","acronym":"","url":"https://clinicaltrials.gov/study/NCT01273168","created_at":"2021-01-18T05:09:01.740Z","updated_at":"2025-02-25T13:39:00.081Z","phase":"Phase 1","brief_title":"Endoxifen in Adults With Hormone Receptor Positive Solid Tumors","source_id_and_acronym":"NCT01273168","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" HER-2","pipe":"","alterations":" ","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e tamoxifen • Zonalta (Z-endoxifen hydrochloride)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 40","initiation":"Initiation: 03/01/2011","start_date":" 03/01/2011","primary_txt":" Primary completion: 06/01/2020","primary_completion_date":" 06/01/2020","study_txt":" Completion: 06/01/2026","study_completion_date":" 06/01/2026","last_update_posted":"2025-02-21"},{"id":"909260a0-1d22-47e9-9081-eb961f7d0511","acronym":"","url":"https://clinicaltrials.gov/study/NCT06184750","created_at":"2023-12-28T15:17:32.895Z","updated_at":"2025-02-25T13:42:00.077Z","phase":"Phase 2","brief_title":"Finding the Best Tamoxifen Dose for Breast Cancer Risk Reduction in Premenopausal Women, RENAISSANCE Trial","source_id_and_acronym":"NCT06184750","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" ADAR","pipe":"","alterations":" ","tags":["ADAR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e tamoxifen"],"overall_status":"Recruiting","enrollment":" Enrollment 200","initiation":"Initiation: 09/27/2024","start_date":" 09/27/2024","primary_txt":" Primary completion: 07/30/2027","primary_completion_date":" 07/30/2027","study_txt":" Completion: 07/30/2027","study_completion_date":" 07/30/2027","last_update_posted":"2025-02-21"},{"id":"db930c87-92ac-41c5-ad78-232d08feae0d","acronym":"","url":"https://clinicaltrials.gov/study/NCT00949598","created_at":"2021-01-18T03:41:34.600Z","updated_at":"2025-02-25T14:48:25.058Z","phase":"Phase 3","brief_title":"Letrozole or Tamoxifen Citrate in Treating Older Postmenopausal Women Undergoing Surgery for Breast Cancer","source_id_and_acronym":"NCT00949598","lead_sponsor":"Institut du Cancer de Montpellier - Val d'Aurelle","biomarkers":" ER • PCNA","pipe":" | ","alterations":" ER positive","tags":["ER • PCNA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ER positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e tamoxifen • letrozole • Soltamox (tamoxifen citrate)"],"overall_status":"Completed","enrollment":" Enrollment 177","initiation":"Initiation: 12/01/2008","start_date":" 12/01/2008","primary_txt":" Primary completion: 10/01/2010","primary_completion_date":" 10/01/2010","study_txt":" Completion: 10/01/2010","study_completion_date":" 10/01/2010","last_update_posted":"2025-02-13"},{"id":"996991a4-16ed-4414-90f1-2f630a1b4a1d","acronym":"lidERA Breast Cancer","url":"https://clinicaltrials.gov/study/NCT04961996","created_at":"2021-07-14T14:53:31.141Z","updated_at":"2025-02-25T15:35:10.567Z","phase":"Phase 3","brief_title":"A Study Evaluating the Efficacy and Safety of Adjuvant Giredestrant Compared With Physician's Choice of Adjuvant Endocrine Monotherapy in Participants With Estrogen Receptor-Positive, HER2-Negative Early Breast Cancer (lidERA Breast Cancer)","source_id_and_acronym":"NCT04961996 - lidERA Breast Cancer","lead_sponsor":"Hoffmann-La Roche","biomarkers":" HER-2 • ER","pipe":" | ","alterations":" ER positive • HER-2 negative","tags":["HER-2 • ER"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ER positive • HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e tamoxifen • Verzenio (abemaciclib) • giredestrant (RG6171)"],"overall_status":"Recruiting","enrollment":" Enrollment 4200","initiation":"Initiation: 08/27/2021","start_date":" 08/27/2021","primary_txt":" Primary completion: 03/31/2026","primary_completion_date":" 03/31/2026","study_txt":" Completion: 11/21/2033","study_completion_date":" 11/21/2033","last_update_posted":"2025-02-10"},{"id":"0d7fca80-0420-4ead-a6c7-20e34e32d1a2","acronym":"pionERA Breast Cancer","url":"https://clinicaltrials.gov/study/NCT06065748","created_at":"2023-10-04T16:11:25.824Z","updated_at":"2025-02-25T16:47:04.424Z","phase":"Phase 3","brief_title":"A Study to Evaluate Efficacy and Safety of Giredestrant Compared With Fulvestrant (Plus a CDK4/6 Inhibitor), in Participants With ER-Positive, HER2-Negative Advanced Breast Cancer Resistant to Adjuvant Endocrine Therapy (pionERA Breast Cancer)","source_id_and_acronym":"NCT06065748 - pionERA Breast Cancer","lead_sponsor":"Hoffmann-La Roche","biomarkers":" HER-2 • ER • CDK4","pipe":" | ","alterations":" ER positive • HER-2 negative • HER-2 negative + ER positive • HER-2 negative + ER positive + ESR1 mutation","tags":["HER-2 • ER • CDK4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ER positive • HER-2 negative • HER-2 negative + ER positive • HER-2 negative + ER positive + ESR1 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Ibrance (palbociclib) • Verzenio (abemaciclib) • Kisqali (ribociclib) • fulvestrant • giredestrant (RG6171)"],"overall_status":"Recruiting","enrollment":" Enrollment 1050","initiation":"Initiation: 12/11/2023","start_date":" 12/11/2023","primary_txt":" Primary completion: 07/30/2026","primary_completion_date":" 07/30/2026","study_txt":" Completion: 12/30/2028","study_completion_date":" 12/30/2028","last_update_posted":"2025-02-05"},{"id":"432f1e5f-02a6-4552-b299-64f4b470c25a","acronym":"heredERA","url":"https://clinicaltrials.gov/study/NCT05296798","created_at":"2022-04-20T16:53:29.043Z","updated_at":"2025-02-25T12:28:43.790Z","phase":"Phase 3","brief_title":"A Study to Evaluate the Efficacy and Safety of Giredestrant in Combination With Phesgo (Pertuzumab, Trastuzumab, and Hyaluronidase-zzxf) Versus Phesgo in Participants With Locally Advanced or Metastatic Breast Cancer (heredERA Breast Cancer)","source_id_and_acronym":"NCT05296798 - heredERA","lead_sponsor":"Hoffmann-La Roche","biomarkers":" HER-2 • ER","pipe":" | ","alterations":" ER positive • EGFR positive","tags":["HER-2 • ER"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ER positive • EGFR positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e paclitaxel • docetaxel • tamoxifen • Perjeta (pertuzumab) • giredestrant (RG6171) • Phesgo (pertuzumab/trastuzumab/hyaluronidase-zzxf)"],"overall_status":"Recruiting","enrollment":" Enrollment 922","initiation":"Initiation: 07/04/2022","start_date":" 07/04/2022","primary_txt":" Primary completion: 03/31/2027","primary_completion_date":" 03/31/2027","study_txt":" Completion: 12/31/2030","study_completion_date":" 12/31/2030","last_update_posted":"2025-02-04"},{"id":"65c1ec6b-055f-4603-b88a-18648345da78","acronym":"EMPRESS","url":"https://clinicaltrials.gov/study/NCT05659563","created_at":"2022-12-21T15:59:16.652Z","updated_at":"2025-02-25T16:54:37.319Z","phase":"Phase 2","brief_title":"Preoperative Window Opportunity Study With Giredestrant or Tamoxifen in Premenopausal Women With ER+/HER2[-] \u0026 Ki67≥10%","source_id_and_acronym":"NCT05659563 - EMPRESS","lead_sponsor":"MedSIR","biomarkers":" HER-2 • ER","pipe":" | ","alterations":" HER-2 negative","tags":["HER-2 • ER"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e tamoxifen • giredestrant (RG6171) • Soltamox (tamoxifen citrate)"],"overall_status":"Completed","enrollment":" Enrollment 92","initiation":"Initiation: 07/20/2023","start_date":" 07/20/2023","primary_txt":" Primary completion: 01/30/2025","primary_completion_date":" 01/30/2025","study_txt":" Completion: 01/30/2025","study_completion_date":" 01/30/2025","last_update_posted":"2025-02-04"},{"id":"55cb45be-28da-426b-95b0-c684a21c9966","acronym":"","url":"https://clinicaltrials.gov/study/NCT02311933","created_at":"2021-01-18T10:56:52.952Z","updated_at":"2025-02-25T16:58:44.113Z","phase":"Phase 2","brief_title":"Tamoxifen Citrate or Z-Endoxifen Hydrochloride in Treating Patients With Locally Advanced or Metastatic, Estrogen Receptor-Positive, HER2-Negative Breast Cancer","source_id_and_acronym":"NCT02311933","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" ER • NCOA3","pipe":" | ","alterations":" ER positive • HER-2 negative • ER positive + HER-2 negative • HER-2 negative + ER positive","tags":["ER • NCOA3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ER positive • HER-2 negative • ER positive + HER-2 negative • HER-2 negative + ER positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Zonalta (Z-endoxifen hydrochloride) • Soltamox (tamoxifen citrate)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 81","initiation":"Initiation: 05/28/2015","start_date":" 05/28/2015","primary_txt":" Primary completion: 11/06/2020","primary_completion_date":" 11/06/2020","study_txt":" Completion: 02/04/2025","study_completion_date":" 02/04/2025","last_update_posted":"2025-02-03"},{"id":"61d86a30-55c7-41a4-bec4-37a547f93c03","acronym":"OP-1250-003","url":"https://clinicaltrials.gov/study/NCT05508906","created_at":"2022-08-19T17:10:19.756Z","updated_at":"2025-02-25T15:54:36.272Z","phase":"Phase 1","brief_title":"Phase 1b Combo w/ Ribociclib, Alpelisib, or Everolimus","source_id_and_acronym":"NCT05508906 - OP-1250-003","lead_sponsor":"Olema Pharmaceuticals, Inc.","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 negative","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e everolimus • Piqray (alpelisib) • Kisqali (ribociclib) • palazestrant (OP-1250)"],"overall_status":"Recruiting","enrollment":" Enrollment 155","initiation":"Initiation: 08/31/2022","start_date":" 08/31/2022","primary_txt":" Primary completion: 05/20/2026","primary_completion_date":" 05/20/2026","study_txt":" Completion: 06/30/2026","study_completion_date":" 06/30/2026","last_update_posted":"2024-10-03"},{"id":"072b5222-7280-4f30-8150-3b6f5d947d3d","acronym":"","url":"https://clinicaltrials.gov/study/NCT02228681","created_at":"2024-01-03T20:17:23.392Z","updated_at":"2025-02-25T15:41:52.541Z","phase":"Phase 2","brief_title":"Everolimus and Letrozole or Hormonal Therapy to Treat Endometrial Cancer","source_id_and_acronym":"NCT02228681","lead_sponsor":"GOG Foundation","biomarkers":" PIK3CA • PGR • PTEN • CTNNB1","pipe":" | ","alterations":" KRAS mutation • PIK3CA mutation","tags":["PIK3CA • PGR • PTEN • CTNNB1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS mutation • PIK3CA mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e everolimus • tamoxifen • letrozole"],"overall_status":"Completed","enrollment":" Enrollment 74","initiation":"Initiation: 05/21/2015","start_date":" 05/21/2015","primary_txt":" Primary completion: 01/01/2018","primary_completion_date":" 01/01/2018","study_txt":" Completion: 08/22/2024","study_completion_date":" 08/22/2024","last_update_posted":"2024-09-19"},{"id":"469f79f5-7bed-470f-bde8-dd6a3a9d7203","acronym":"GO39932","url":"https://clinicaltrials.gov/study/NCT03332797","created_at":"2021-01-17T18:03:30.772Z","updated_at":"2024-07-02T16:34:37.744Z","phase":"Phase 1","brief_title":"A Study of GDC-9545 Alone or in Combination With Palbociclib and/or Luteinizing Hormone-Releasing Hormone (LHRH) Agonist in Locally Advanced or Metastatic Estrogen Receptor-Positive Breast Cancer","source_id_and_acronym":"NCT03332797 - GO39932","lead_sponsor":"Genentech, Inc.","biomarkers":" HER-2 • ER","pipe":" | ","alterations":" HER-2 positive • ER positive • HER-2 negative • ER positive + HER-2 negative","tags":["HER-2 • ER"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive • ER positive • HER-2 negative • ER positive + HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Ibrance (palbociclib) • triptorelin • goserelin acetate • giredestrant (RG6171)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 181","initiation":"Initiation: 11/27/2017","start_date":" 11/27/2017","primary_txt":" Primary completion: 06/30/2025","primary_completion_date":" 06/30/2025","study_txt":" Completion: 06/30/2025","study_completion_date":" 06/30/2025","last_update_posted":"2024-06-06"},{"id":"9b710d7c-4f9a-4b68-bdf9-a2e98a847a66","acronym":"acelERA BC","url":"https://clinicaltrials.gov/study/NCT04576455","created_at":"2021-03-16T19:52:58.652Z","updated_at":"2024-07-02T16:34:37.881Z","phase":"Phase 2","brief_title":"A Study Evaluating the Efficacy and Safety of Giredestrant Compared With Physician's Choice of Endocrine Monotherapy in Participants With Previously Treated Estrogen Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer (acelERA Breast Cancer)","source_id_and_acronym":"NCT04576455 - acelERA BC","lead_sponsor":"Hoffmann-La Roche","biomarkers":" HER-2 • ER","pipe":" | ","alterations":" ER positive • HER-2 negative","tags":["HER-2 • ER"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ER positive • HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e fulvestrant • giredestrant (RG6171)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 303","initiation":"Initiation: 11/27/2020","start_date":" 11/27/2020","primary_txt":" Primary completion: 02/18/2022","primary_completion_date":" 02/18/2022","study_txt":" Completion: 06/27/2025","study_completion_date":" 06/27/2025","last_update_posted":"2024-06-06"},{"id":"1250c179-6562-4901-865f-17545e9bd303","acronym":"ML43171","url":"https://clinicaltrials.gov/study/NCT05306340","created_at":"2022-04-01T21:53:28.059Z","updated_at":"2024-07-02T16:34:58.786Z","phase":"Phase 3","brief_title":"A Study Evaluating the Efficacy and Safety of Giredestrant Plus Everolimus Compared With The Physician's Choice of Endocrine Therapy Plus Everolimus in Participants With Estrogen Receptor-Positive, HER2-Negative, Locally Advanced or Metastatic Breast Cancer (evERA Breast Cancer)","source_id_and_acronym":"NCT05306340 - ML43171","lead_sponsor":"Genentech, Inc.","biomarkers":" HER-2 • ER","pipe":" | ","alterations":" ER positive • HER-2 negative • ESR1 mutation","tags":["HER-2 • ER"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ER positive • HER-2 negative • ESR1 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e everolimus • tamoxifen • fulvestrant • dexamethasone • exemestane • giredestrant (RG6171)"],"overall_status":"Recruiting","enrollment":" Enrollment 320","initiation":"Initiation: 08/03/2022","start_date":" 08/03/2022","primary_txt":" Primary completion: 10/03/2024","primary_completion_date":" 10/03/2024","study_txt":" Completion: 03/31/2026","study_completion_date":" 03/31/2026","last_update_posted":"2024-06-05"},{"id":"ce41ba1f-4d4f-4c72-ae06-d61cb6cc53c7","acronym":"","url":"https://clinicaltrials.gov/study/NCT04546009","created_at":"2021-01-18T21:44:38.264Z","updated_at":"2024-07-02T16:34:58.754Z","phase":"Phase 3","brief_title":"A Study Evaluating the Efficacy and Safety of Giredestrant Combined With Palbociclib Compared With Letrozole Combined With Palbociclib in Participants With Estrogen Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer (persevERA Breast Cancer)","source_id_and_acronym":"NCT04546009","lead_sponsor":"Hoffmann-La Roche","biomarkers":" HER-2 • ER","pipe":" | ","alterations":" ER positive • HER-2 negative • ER positive + HER-2 negative","tags":["HER-2 • ER"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ER positive • HER-2 negative • ER positive + HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Ibrance (palbociclib) • letrozole • giredestrant (RG6171)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 992","initiation":"Initiation: 10/09/2020","start_date":" 10/09/2020","primary_txt":" Primary completion: 03/31/2025","primary_completion_date":" 03/31/2025","study_txt":" Completion: 03/18/2027","study_completion_date":" 03/18/2027","last_update_posted":"2024-06-05"},{"id":"7d23d816-d6f4-41e9-9cb9-d2526c0cc2b3","acronym":"OPERA-01","url":"https://clinicaltrials.gov/study/NCT06016738","created_at":"2023-08-30T14:08:41.909Z","updated_at":"2024-07-02T16:34:59.724Z","phase":"Phase 3","brief_title":"OP-1250 (Palazestrant) vs. Standard of Care for the Treatment of ER+/HER2- Advanced Breast Cancer","source_id_and_acronym":"NCT06016738 - OPERA-01","lead_sponsor":"Olema Pharmaceuticals, Inc.","biomarkers":" HER-2 • ER","pipe":" | ","alterations":" HER-2 negative • ESR1 mutation","tags":["HER-2 • ER"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative • ESR1 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e fulvestrant • letrozole • anastrozole • exemestane • palazestrant (OP-1250)"],"overall_status":"Recruiting","enrollment":" Enrollment 510","initiation":"Initiation: 11/16/2023","start_date":" 11/16/2023","primary_txt":" Primary completion: 06/30/2026","primary_completion_date":" 06/30/2026","study_txt":" Completion: 09/30/2027","study_completion_date":" 09/30/2027","last_update_posted":"2024-05-31"},{"id":"d4742e3b-806e-4bab-ae68-fb132b73b498","acronym":"MiRaDoR","url":"https://clinicaltrials.gov/study/NCT05708235","created_at":"2023-02-01T15:00:03.847Z","updated_at":"2024-07-02T16:35:00.523Z","phase":"Phase 2","brief_title":"A PoC Study to Evaluate Treatments' Efficacy by Monitoring MRD Using ctDNA in HR-positive/HER2-negative EBC Population","source_id_and_acronym":"NCT05708235 - MiRaDoR","lead_sponsor":"MedSIR","biomarkers":" HER-2 • PIK3CA","pipe":" | ","alterations":" HR positive • HER-2 negative • PIK3CA mutation","tags":["HER-2 • PIK3CA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HR positive • HER-2 negative • PIK3CA mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Verzenio (abemaciclib) • Itovebi (inavolisib) • giredestrant (RG6171)"],"overall_status":"Recruiting","enrollment":" Enrollment 1260","initiation":"Initiation: 04/01/2024","start_date":" 04/01/2024","primary_txt":" Primary completion: 12/30/2028","primary_completion_date":" 12/30/2028","study_txt":" Completion: 12/30/2028","study_completion_date":" 12/30/2028","last_update_posted":"2024-05-29"},{"id":"eaaf2dfa-c846-4367-bf8f-9784501b61fc","acronym":"MUSCLE-CLIM","url":"https://clinicaltrials.gov/study/NCT05690295","created_at":"2023-01-19T14:59:40.218Z","updated_at":"2024-07-02T16:35:03.126Z","phase":"","brief_title":"Resistance-type Exercise Training in Postmenopausal Women Survivors of Breast Cancer","source_id_and_acronym":"NCT05690295 - MUSCLE-CLIM","lead_sponsor":"Universidad de La Frontera","biomarkers":" ER","pipe":"","alterations":" ","tags":["ER"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e tamoxifen"],"overall_status":"Completed","enrollment":" Enrollment 26","initiation":"Initiation: 03/22/2023","start_date":" 03/22/2023","primary_txt":" Primary completion: 03/29/2024","primary_completion_date":" 03/29/2024","study_txt":" Completion: 05/15/2024","study_completion_date":" 05/15/2024","last_update_posted":"2024-05-17"},{"id":"e915b737-ffd0-45cb-831e-4df90b73590c","acronym":"","url":"https://clinicaltrials.gov/study/NCT02206984","created_at":"2021-01-18T10:20:00.102Z","updated_at":"2024-07-02T16:35:03.969Z","phase":"Phase 2","brief_title":"Endocrine Response in Women With Invasive Lobular Breast Cancer","source_id_and_acronym":"NCT02206984","lead_sponsor":"Priscilla McAuliffe","biomarkers":" HER-2","pipe":" | ","alterations":" HR positive • HER-2 negative • HR positive + HER-2 negative • PTEN mutation + HR positive","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HR positive • HER-2 negative • HR positive + HER-2 negative • PTEN mutation + HR positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e tamoxifen • fulvestrant • anastrozole"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 201","initiation":"Initiation: 09/30/2015","start_date":" 09/30/2015","primary_txt":" Primary completion: 07/31/2024","primary_completion_date":" 07/31/2024","study_txt":" Completion: 07/31/2024","study_completion_date":" 07/31/2024","last_update_posted":"2024-05-14"},{"id":"bbda9792-84c4-4dce-9170-dd7e926b7ce7","acronym":"HORMONET","url":"https://clinicaltrials.gov/study/NCT03870399","created_at":"2021-01-18T19:05:05.750Z","updated_at":"2024-07-02T16:35:05.851Z","phase":"Phase 2","brief_title":"Study of Tamoxifen in Well Differentiated Neuroendocrine Tumors and Hormone Receptor Positive Expression","source_id_and_acronym":"NCT03870399 - HORMONET","lead_sponsor":"AC Camargo Cancer Center","biomarkers":" PGR • CHGA","pipe":"","alterations":" ","tags":["PGR • CHGA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e tamoxifen"],"overall_status":"Completed","enrollment":" Enrollment 23","initiation":"Initiation: 03/13/2019","start_date":" 03/13/2019","primary_txt":" Primary completion: 05/13/2023","primary_completion_date":" 05/13/2023","study_txt":" Completion: 05/13/2023","study_completion_date":" 05/13/2023","last_update_posted":"2024-05-06"},{"id":"fb05cd3f-10d1-4b7d-9490-18dfc2923550","acronym":"","url":"https://clinicaltrials.gov/study/NCT05156606","created_at":"2021-12-14T12:53:37.114Z","updated_at":"2024-07-02T16:35:05.978Z","phase":"","brief_title":"Testosterone \u0026 Tamoxifen Trial","source_id_and_acronym":"NCT05156606","lead_sponsor":"University Medical Center Groningen","biomarkers":" HER-2 • CDK4","pipe":" | ","alterations":" HER-2 negative","tags":["HER-2 • CDK4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e tamoxifen"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 5","initiation":"Initiation: 11/10/2022","start_date":" 11/10/2022","primary_txt":" Primary completion: 10/03/2024","primary_completion_date":" 10/03/2024","study_txt":" Completion: 10/03/2024","study_completion_date":" 10/03/2024","last_update_posted":"2024-05-03"},{"id":"c21c3175-7382-4f1a-8820-9704f21fd83d","acronym":"MORE-T","url":"https://clinicaltrials.gov/study/NCT04997941","created_at":"2021-08-10T14:52:49.249Z","updated_at":"2024-07-02T16:35:08.172Z","phase":"Phase 2","brief_title":"Higher Dose Preoperative taMOxifen in Premenopausal bREast Cancer Patients","source_id_and_acronym":"NCT04997941 - MORE-T","lead_sponsor":"Seoul National University Hospital","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 negative","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e tamoxifen"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 238","initiation":"Initiation: 10/21/2021","start_date":" 10/21/2021","primary_txt":" Primary completion: 12/31/2024","primary_completion_date":" 12/31/2024","study_txt":" Completion: 12/31/2028","study_completion_date":" 12/31/2028","last_update_posted":"2024-04-23"},{"id":"f959eeb0-3b0b-4ca2-b45f-49dbe8ed0379","acronym":"PREcoopERA","url":"https://clinicaltrials.gov/study/NCT05896566","created_at":"2023-06-09T16:06:48.058Z","updated_at":"2024-07-02T16:35:11.267Z","phase":"Phase 2","brief_title":"A Window-of-Opportunity Trial of Giredestrant +/- Triptorelin vs. Anastrozole + Triptorelin in Premenopausal Patients With ER-positive/HER2-negative Early Breast Cancer","source_id_and_acronym":"NCT05896566 - PREcoopERA","lead_sponsor":"ETOP IBCSG Partners Foundation","biomarkers":" HER-2 • ER","pipe":" | ","alterations":" ER positive • HER-2 negative","tags":["HER-2 • ER"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ER positive • HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e anastrozole • triptorelin • giredestrant (RG6171)"],"overall_status":"Recruiting","enrollment":" Enrollment 220","initiation":"Initiation: 01/23/2024","start_date":" 01/23/2024","primary_txt":" Primary completion: 06/01/2026","primary_completion_date":" 06/01/2026","study_txt":" Completion: 06/01/2026","study_completion_date":" 06/01/2026","last_update_posted":"2024-04-05"},{"id":"3f6cd9fc-5844-4b4e-b706-82899db0d8c4","acronym":"NSABP B-42","url":"https://clinicaltrials.gov/study/NCT00382070","created_at":"2021-01-18T01:19:44.480Z","updated_at":"2025-02-25T15:48:05.276Z","phase":"Phase 3","brief_title":"Letrozole in Treating Postmenopausal Women Who Have Received Hormone Therapy for Hormone Receptor-Positive Breast Cancer","source_id_and_acronym":"NCT00382070 - NSABP B-42","lead_sponsor":"NSABP Foundation Inc","biomarkers":" ER • PGR","pipe":" | ","alterations":" ER positive","tags":["ER • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ER positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e tamoxifen • letrozole"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 3966","initiation":"Initiation: 08/01/2006","start_date":" 08/01/2006","primary_txt":" Primary completion: 08/25/2016","primary_completion_date":" 08/25/2016","study_txt":" Completion: 04/01/2025","study_completion_date":" 04/01/2025","last_update_posted":"2024-03-22"}]